Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Iradimed (IRMD) over the last 13 years, with Q3 2025 value amounting to $66.3 million.

  • Iradimed's Retained Earnings rose 2390.09% to $66.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.3 million, marking a year-over-year increase of 2390.09%. This contributed to the annual value of $56.8 million for FY2024, which is 3128.33% up from last year.
  • As of Q3 2025, Iradimed's Retained Earnings stood at $66.3 million, which was up 2390.09% from $62.9 million recorded in Q2 2025.
  • In the past 5 years, Iradimed's Retained Earnings registered a high of $66.3 million during Q3 2025, and its lowest value of $36.9 million during Q1 2022.
  • Moreover, its 5-year median value for Retained Earnings was $46.7 million (2023), whereas its average is $47.5 million.
  • In the last 5 years, Iradimed's Retained Earnings plummeted by 847.6% in 2023 and then soared by 3128.33% in 2024.
  • Quarter analysis of 5 years shows Iradimed's Retained Earnings stood at $47.0 million in 2021, then increased by 0.57% to $47.3 million in 2022, then decreased by 8.48% to $43.3 million in 2023, then surged by 31.28% to $56.8 million in 2024, then rose by 16.82% to $66.3 million in 2025.
  • Its last three reported values are $66.3 million in Q3 2025, $62.9 million for Q2 2025, and $59.3 million during Q1 2025.